CDTX(Delisted)
Cidara Therapeutics (CDTX) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Cidara Therapeutics market cap is -- and enterprise value is --.
Share Statistics
Cidara Therapeutics has 31.44M shares outstanding, with a free float of 24.77M.
Valuation Ratios
Cidara Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Cidara Therapeutics debt-to-equity ratio is 0 and debt-to-assets ratio is 0.19.
Liquidity
Cidara Therapeutics's current ratio is 4.62, quick ratio is 4.62, and cash ratio is 4.38, showing its short-term liquidity position.
Return on Capital
Cidara Therapeutics's ROE is -68.67%, ROA is -54.26%, and ROIC is -72.66%, showing its return on capital profile.
Profitability
Cidara Therapeutics gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
Cidara Therapeutics's asset turnover is 0, inventory turnover is --, and receivables turnover is 0, indicating its operating efficiency.
Income Statement
Cidara Therapeutics's revenue is --, gross profit is --, net income is -184.74M, and EBITDA is -195.30M.
Balance Sheet
Cidara Therapeutics's total debt is 0, net debt is 0, total equity is 422.39M, and cash is 420.02M.
Cash Flow Statement
Cidara Therapeutics's operating cash flow is -132.94M, free cash flow is -132.94M, and CapEx is 0.
Dividends & Yields
Cidara Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Cidara Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A biotech company that develops long-acting therapeutics
Per Share Metrics
Cidara Therapeutics's EPS is -11.22, book value per share is 14.4, and free cash flow per share is --.
